The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Isocitrate dehydrogenase mutations in myeloid malignancies
Open accessAbstract
Alterations to genes involved in cellular metabolism and epigenetic regulation are implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate dehydrogenase (IDH) genes are detected in approximately 20% of adult patients with acute myeloid leukemia (AML) and 5% of adults with myelodysplastic syndromes (MDS). IDH proteins are homodimeric enzymes involved in diverse cellular processes, including adaptation to hypoxia, histone demethylation and DNA modification. The IDH2 protein is localized in the mitochondria and is a critical component of the tricarboxylic acid (also called the 'citric acid' or Krebs) cycle. Both IDH2 and IDH1 (localized in the cytoplasm) proteins catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG). Mutant IDH enzymes have neomorphic activity and catalyze reduction of α-KG to the (R) enantiomer of 2-hydroxyglutarate, which is associated with DNA and histone hypermethylation, altered gene expression and blocked differentiation of hematopoietic progenitor cells. The prognostic significance of mutant IDH (mIDH) is controversial but appears to be influenced by co-mutational status and the specific location of the mutation (IDH1-R132, IDH2-R140, IDH2-R172). Treatments specifically or indirectly targeted to mIDH are currently under clinical investigation; these therapies have been generally well tolerated and, when used as single agents, have shown promise for inducing responses in some mIDH patients when used as first-line treatment or in relapsed or refractory AML or MDS. Use of mIDH inhibitors in combination with drugs with non-overlapping mechanisms of action is especially promising, as such regimens may address the clonal heterogeneity and the multifactorial pathogenic processes involved in mIDH myeloid malignancies. Advances in mutational analysis have made testing more rapid and convenient, and less expensive; such testing should become part of routine diagnostic workup and repeated at relapse to identify patients who may benefit from treatments that target mIDH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Marcucci, G., Maharry, K., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 763
Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324297111 · Cited by 705
Self-citation( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., Zhao, F., Medeiros, B. C., Tyvoll, D. A., & Majeti, R. (2015) · Nature Medicine · doi:10.1038/nm.3788 · Cited by 577
Self-citationWhat a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Losman, J.-A., & Kaelin, W. G. (2013) · Genes & Development · doi:10.1101/gad.217406.113 · Cited by 570
Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis
McKerrell, T., Park, N., Moreno, T., Grove, C. S., Ponstingl, H., Stephens, J., Crawley, C., Craig, J., Scott, M. A., Hodkinson, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.005 · Cited by 534
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K.-L., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 458
Abbas, S., Lugthart, S., Kavelaars, F. G., Schelen, A., Koenders, J. E., Zeilemaker, A., van Putten, W. J. L., Rijneveld, A. W., Löwenberg, B., & Valk, P. J. M. (2010) · Blood · doi:10.1182/blood-2009-11-250878 · Cited by 393
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
DiNardo, C. D., Ravandi, F., Agresta, S., Konopleva, M., Takahashi, K., Kadia, T., Routbort, M., Patel, K. P., Brandt, M., Pierce, S., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24072 · Cited by 325
Self-citationThe prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Green, C. L., Evans, C. M., Zhao, L., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2011) · Blood · doi:10.1182/blood-2010-12-322479 · Cited by 268
Im, A. P., Sehgal, A. R., Carroll, M. P., Smith, B. D., Tefferi, A., Johnson, D. E., & Boyiadzis, M. (2014) · Leukemia · doi:10.1038/leu.2014.124 · Cited by 267
Rampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Pronier, E., Patel, J., Li, Y., Ahn, J., Abdel-Wahab, O., Shih, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.004 · Cited by 261
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Abdel-Wahab, O., & Levine, R. L. (2013) · Blood · doi:10.1182/blood-2013-01-451781 · Cited by 249
Wagner, K., Damm, F., Göhring, G., Görlich, K., Heuser, M., Schäfer, I., Ottmann, O., Lübbert, M., Heit, W., Kanz, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6899 · Cited by 241
Boissel, N., Nibourel, O., Renneville, A., Gardin, C., Reman, O., Contentin, N., Bordessoule, D., Pautas, C., de Revel, T., Quesnel, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.2285 · Cited by 222
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491571 · Cited by 210
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
Clark, O., Yen, K., & Mellinghoff, I. K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1333 · Cited by 206
Chou, W.-C., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Ko, B.-S., Wu, S.-J., Huang, S.-Y., Hsu, S.-C., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253070 · Cited by 204
Schnittger, S., Haferlach, C., Ulke, M., Alpermann, T., Kern, W., & Haferlach, T. (2010) · Blood · doi:10.1182/blood-2010-02-267955 · Cited by 199
DiNardo, C. D., Propert, K. J., Loren, A. W., Paietta, E., Sun, Z., Levine, R. L., Straley, K. S., Yen, K., Patel, J. P., Agresta, S., et al. (2013) · Blood · doi:10.1182/blood-2013-03-493197 · Cited by 198
Self-citationEmerging therapeutic drugs for AML
Stein, E. M., & Tallman, M. S. (2016) · Blood · doi:10.1182/blood-2015-07-604538 · Cited by 194
Thol, F., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 191
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Thol, F., Damm, F., Wagner, K., Göhring, G., Schlegelberger, B., Hoelzer, D., Lübbert, M., Heit, W., Kanz, L., Schlimok, G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272146 · Cited by 186
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
Pardanani, A., Lasho, T. L., Finke, C. M., Mai, M., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.77 · Cited by 184
Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., van Noorden, C. J. F., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 182
Ward, P. S., Lu, C., Cross, J. R., Abdel-Wahab, O., Levine, R. L., Schwartz, G. K., & Thompson, C. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.435495 · Cited by 181
Acute Myeloid Leukemia With IDH1 or IDH2 Mutation
Patel, K. P., Ravandi, F., Ma, D., Paladugu, A., Barkoh, B. A., Medeiros, L. J., & Luthra, R. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpd7nr2rmnqdvf · Cited by 178
Chou, W.-C., Lei, W.-C., Ko, B.-S., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Wu, S.-J., Huang, S.-Y., et al. (2011) · Leukemia · doi:10.1038/leu.2010.267 · Cited by 177
Metabolism unhinged: IDH mutations in cancer
Prensner, J. R., & Chinnaiyan, A. M. (2011) · Nature Medicine · doi:10.1038/nm0311-291 · Cited by 172
Kernytsky, A., Wang, F., Hansen, E., Schalm, S., Straley, K., Gliser, C., Yang, H., Travins, J., Murray, S., Dorsch, M., et al. (2015) · Blood · doi:10.1182/blood-2013-10-533604 · Cited by 172
Emadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., & Dang, C. V. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.001 · Cited by 167
Self-citationLasho, T. L., Jimma, T., Finke, C. M., Patnaik, M., Hanson, C. A., Ketterling, R. P., Pardanani, A., & Tefferi, A. (2012) · Blood · doi:10.1182/blood-2012-05-429696 · Cited by 167
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Wang, J.-H., Chen, W., Li, J., Wu, S., Chen, T., Zhu, Y., Zhang, W., Li, Y., Qiu, Y.-P., Zhao, A.-H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315558110 · Cited by 148
Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.298 · Cited by 147
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1407-8 · Cited by 142
Self-citationDisruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 132
Janin, M., Mylonas, E., Saada, V., Micol, J., Renneville, A., Quivoron, C., Koscielny, S., Scourzic, L., Forget, S., Pautas, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2047 · Cited by 131
Myelodysplastic syndrome is not merely “preleukemia”
Albitar, M. X., Manshouri, T., Shen, Y., Liu, D., Beran, M., Kantarjian, H. M., Rogers, A. M., Jilani, I. B., Lin, C., Pierce, S. A., et al. (2002) · Blood · doi:10.1182/blood.v100.3.791 · Cited by 129
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M. E., Lopez, H. U., Matulis, C. R., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438267 · Cited by 125
Self-citationIDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
Dinardo, C. D., Jabbour, E. J., Ravandi, F., Takahashi, K., Daver, N. G., Routbort, M. J., Patel, K. P., Brandt, M., Pierce, S. A., Kantarjian, H. M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.211 · Cited by 119
Self-citationThe Epigenetic Landscape of Acute Myeloid Leukemia
O’Brien, E. C., Prideaux, S. M., & Chevassut, T. J. T. (2014) · Advances in Hematology · doi:10.1155/2014/103175 · Cited by 117
Chotirat, S., Thongnoppakhun, W., Promsuwicha, O., Boonthimat, C., & Auewarakul, C. U. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-5 · Cited by 116
Li, L., Paz, A. C., Wilky, B. A., Johnson, B. A., Galoian, K. A., Rosenberg, A. E., Hu, G., Tinoco, G., Bodamer, O. A., & Trent, J. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133813 · Cited by 115
Debarri, H., Lebon, D., Roumier, C., Cheok, M. H.-C., Marceau‐Renaut, A., Nibourel, O., Geffroy, S., Hélevaut, N., Rousselot, P. H., Gruson, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5645 · Cited by 108
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B. J., Clemente, M. J., Przychodzen, B. P., Hirsch, C. M., Viny, A. D., Hosano, N., Bleeker, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.91 · Cited by 103
Emerging Roles of JmjC Domain-Containing Proteins
Accari, S. L., & Fisher, P. R. (2015) · International review of cytology · doi:10.1016/bs.ircmb.2015.07.003 · Cited by 97
Lin, C., Hou, H., Chou, W., Kuo, Y., Liu, C., Chen, C., Lai, Y.-J., Tseng, M., Huang, C., Chiang, Y., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23596 · Cited by 85
Estey, E. H., Levine, R. L., & Löwenberg, B. (2015) · Blood · doi:10.1182/blood-2015-01-561373 · Cited by 85
Emadi, A., Faramand, R. G., Carter‐Cooper, B., Tolu, S. S., Ford, L. A., Lapidus, R. G., Wetzler, M., Wang, E. S., Etemadi, A., & Griffiths, E. A. (2015) · American Journal of Hematology · doi:10.1002/ajh.23965 · Cited by 82
Horbinski, C., Kelly, L. M., Nikiforov, Y. E., Durso, M. B., & Nikiforova, M. N. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090228 · Cited by 80
IDH1 and IDH2: Not Your Typical Oncogenes
Reitman, Z. J., Parsons, D. W., & Yan, H. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.024 · Cited by 75
Dinardo, C. D., Patel, K. P., Garcia‐Manero, G., Luthra, R., Pierce, S. A., Borthakur, G. M., Jabbour, E. J., Kadia, T. M., Pemmaraju, N., Konopleva, M. Y., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.855309 · Cited by 72
Self-citationStein, E. M., Dinardo, C. D., Altman, J. K., Collins, R. H., DeAngelo, D. J., Kantarjian, H. M., Sekeres, M. A., Fathi, A. T., Flinn, I. W., Frankel, A. E., et al. (2015) · Blood · doi:10.1182/blood.v126.23.323.323 · Cited by 72
Self-citationEnzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate
Balß, J., Pusch, S., Beck, A.-C., Herold‐Mende, C. C., Krämer, A., Thiede, C., Buckel, W., Langhans, C., Okun, J. G., & von Deimling, A. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1060-y · Cited by 66
Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia
Patel, K. P., Barkoh, B. A., Chen, Z., Ma, D., Reddy, N., Medeiros, L. J., & Luthra, R. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.06.004 · Cited by 59
A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)
Konopleva, M. Y., Pollyea, D. A., Potluri, J., Chyla, B., Busman, T. A., McKeegan, E. M., Salem, A. H., Zhu, M., Ricker, J. L., Blum, W. G., et al. (2014) · Blood · doi:10.1182/blood.v124.21.118.118 · Cited by 57
Self-citationDinardo, C. D., de Botton, S., Pollyea, D. A., Stein, E. M., Fathi, A. T., Roboz, G. J., Collins, R. H., Swords, R. T., Flinn, I. W., Altman, J. K., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1306.1306 · Cited by 57
Self-citationPrognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.
Feng, J., Guo, X., Chen, Y., Wang, Z.-J., Cheng, Y.-P., & Tang, Y. (2012) · PubMed Central · Cited by 56
Jin, J., Hu, C., Yu, M., Chen, F., Ye, L., Yin, X., Zhuang, Z., & Tong, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100206 · Cited by 56
Genetics of Myelodysplastic Syndromes: New Insights
Graubert, T. A., & Walter, M. J. (2011) · Hematology · doi:10.1182/asheducation-2011.1.543 · Cited by 56
Ravandi, F., Patel, K. P., Luthra, R., Faderl, S. H., Konopleva, M. Y., Kadia, T. M., Brandt, M., Pierce, S. A., Kornblau, S. M., Andreeff, M., et al. (2011) · Cancer · doi:10.1002/cncr.26580 · Cited by 55
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.71 · Cited by 53
Yamaguchi, S., Iwanaga, E., Tokunaga, K., Nanri, T., Shimomura, T., Suzushima, H., Mitsuya, H., & Asou, N. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12271 · Cited by 52
IDH2 inhibition in AML: Finally progress?
Stein, E. M. (2015) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2015.10.016 · Cited by 52
Pollyea, D. A., Dinardo, C. D., Thirman, M. J., Letai, A. G., Wei, A. H., Jonas, B. A., Arellano, M. L., Frattini, M. G., Kantarjian, H. M., Chyla, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7009 · Cited by 50
Self-citationReview of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
Fenaux, P., & Adès, L. (2009) · Leukemia Research · doi:10.1016/s0145-2126(09)70227-9 · Cited by 48
Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia
Fathi, A. T., Wander, S. A., Faramand, R. G., & Emadi, A. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.002 · Cited by 48
Self-citationGetting a handle on hereditary CEBPA mutations
Dinardo, C. D. (2015) · Blood · doi:10.1182/blood-2015-07-657908 · Cited by 46
Self-citationWang, E. S., Frankfurt, O., Orford, K. W., Bennett, M. K., Flinn, I. W., Maris, M. B., & Konopleva, M. Y. (2015) · Blood · doi:10.1182/blood.v126.23.2566.2566 · Cited by 45
Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Boissel, N., Nibourel, O., Renneville, A., Huchette, P., Dombret, H., & Preudhomme, C. (2011) · Blood · doi:10.1182/blood-2010-11-320937 · Cited by 43
Willander, K., Falk, I. J., Chaireti, R., Paul, E., Hermansson, M., Gréen, H., Lotfi, K., & Söderkvist, P. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-18 · Cited by 43
Molecular Pathways: IDH2 Mutations—Co-opting Cellular Metabolism for Malignant Transformation
Stein, E. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0362 · Cited by 42
Platt, M. Y., Fathi, A. T., Borger, D. R., Brunner, A. M., Hasserjian, R. P., Balaj, L., Lum, A. M., Yip, S. S. F., Dias-Santagata, D. C., Zheng, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.06.004 · Cited by 36
Self-citationAref, S., Areida, E.-S. K., Aaal, M. F. A., Adam, O. M., El-Ghonemy, M. S., ElBaiomy, M. A., & Abouzeid, T. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.05.009 · Cited by 35
Enigmas of IDH mutations in hematology/oncology
Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28
Chotirat, S., Thongnoppakhun, W., Wanachiwanawin, W., & Auewarakul, C. U. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.11.017 · Cited by 26
Górniak, P., Ejduk, A., Borg, K., Makuch‐Łasica, H., Nowak, G., Lech‐Marańda, E., Prochorec‐Sobieszek, M., Warzocha, K., & Juszczyński, P. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12566 · Cited by 22
Fan, B., Le, K. N., Manyak, E. L., Liu, H., Prahl, M., Bowden, C. J., Biller, S. A., Agresta, S., & Yang, H. (2015) · Blood · doi:10.1182/blood.v126.23.1310.1310 · Cited by 22
Wang, F., Travins, J. M., Lin, Z., Si, Y., Chen, Y., Powe, J., Murray, S., Zhu, D., Artin, E., Größ, S., et al. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9960-y · Cited by 16
Sloan, C. E., Luskin, M. R., Boccuti, A., Sehgal, A. R., Zhao, J., Daber, R. D., Morrissette, J. J. D., Luger, S. M., Bagg, A., Gimotty, P. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153016 · Cited by 12
Inhibition of mutant IDH1 in acute myeloid leukaemia
Yaqub, F. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71140-4 · Cited by 9
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Self-citationNavigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P., Huang, S. C.-C., Fendt, S.-M., & Ho, P.-C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 733
The emerging role and targetability of the TCA cycle in cancer metabolism
Anderson, N. M., Mucka, P., Kern, J. G., & Feng, H. (2018) · Protein & Cell · doi:10.1007/s13238-017-0451-1 · Cited by 556
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 440
Metadata
- Authors
- Medeiros, B. C., Fathi, A. T., DiNardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R.
- Venue
- Leukemia
- Published
- 2016-10-10
- Volume
- 31
- Issue
- 2
- Pages
- 272-281
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2530614832
- Cited by
- 350
- References
- 100
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.